Emerging biotechnology is no longer a single field but a sprawling ecosystem of tools that are rewriting what biology can do and how fast it can do it. Artificial intelligence is designing proteins that never existed in nature, gene editors are making single-letter corrections to DNA without cutting it open, and pig organs are being transplanted into human patients. What ties these technologies together is a common trajectory: they have moved past proof-of-concept and into the early stages of real-world use, though each carries its own set of unresolved risks.
AI-Designed Proteins
For decades, designing a new protein meant years of trial and error in the lab. Machine learning has compressed that timeline dramatically. AI models can now navigate the vast space of possible protein sequences to predict how a chain of amino acids will fold, what it will bind to, and how it will behave inside a living system. This allows researchers to engineer proteins with specific therapeutic or industrial functions from scratch, rather than tweaking what evolution already produced.
The practical payoff is showing up in drug discovery and biotechnology. AI-driven methods accelerate protein structure prediction, molecular docking, and the modeling of how a molecule’s shape relates to its activity, which in turn supports the design of proteins with improved specificity and safety profiles.1PubMed Central. Artificial intelligence driven protein design and sustainable nanomedicine for advanced theranostics Protein design is being applied across drug development, synthetic biology, and industrial enzymology, with AI enabling precision and speed that were not possible with older computational or purely experimental methods.2Nature Reviews Bioengineering. AI-driven protein design The field is still young enough that most AI-designed proteins are in preclinical testing, but the pipeline is growing fast.
Gene Editing Without the Cut
CRISPR-Cas9 made headlines for its ability to cut DNA at precise locations, but cutting both strands of the double helix is a blunt instrument. It works, but it also introduces unpredictable insertions and deletions at the repair site. A newer generation of editors sidesteps this problem entirely. Base editors chemically convert one DNA letter into another without severing the strand, while prime editors can install any of the twelve possible single-letter swaps, plus small insertions or deletions, using a search-and-replace mechanism.3PubMed Central. CRISPR-Cas9 DNA Base-Editing and Prime-Editing
The appeal is obvious: many genetic diseases are caused by a single wrong letter in a gene. Being able to fix that letter without breaking the chromosome is far cleaner than cutting and hoping the cell repairs itself correctly. Both base editors and prime editors bypass the dependence on double-strand breaks, which makes them potentially more precise than traditional nuclease approaches.4Nature Biotechnology. Genotoxic effects of base and prime editing in human hematopoietic stem cells That said, “more precise” does not mean “perfect.” Research into the unintended genetic effects of these tools, particularly in blood stem cells that would be used for therapies, is ongoing. The technology is promising, but clinical applications are still in early trials.
mRNA Therapies Beyond Vaccines
COVID-19 vaccines introduced billions of people to the concept of mRNA therapeutics, but vaccines are only the beginning. Researchers are developing mRNA-based treatments for cancer, using the same basic idea: deliver a strand of genetic instructions into a cell, let the cell’s own machinery produce the desired protein, and trigger a therapeutic response. In cancer immunotherapy, the goal is to get tumor cells or immune cells to produce proteins that flag the cancer for destruction by the immune system.5PubMed Central. mRNA delivery in cancer immunotherapy
The main challenge is delivery. Naked mRNA degrades almost instantly in the body, so it needs a protective vehicle. Lipid nanoparticles have emerged as the leading delivery system, shielding the mRNA from degradation, ferrying it into target cells, and enabling the expression of tumor-specific proteins that activate immune responses against cancer.6PubMed. Lipid nanoparticle mediated mRNA delivery in cancer immunotherapy Other delivery platforms using polymers and protein-based carriers are also in development. The technology is not limited to cancer: mRNA could eventually be used for protein replacement therapies, gene editing, and cell engineering across a range of diseases.
Pig Organs for Human Patients
The shortage of donor organs kills thousands of people every year. Xenotransplantation, the transplantation of organs from one species to another, has been a theoretical solution for decades, but the human immune system violently rejects unmodified pig tissue. Gene editing has changed the equation. Researchers now knock out pig genes responsible for producing surface molecules that trigger human immune rejection, while simultaneously inserting human genes that help the organ evade immune attack.7Transplant International. Current Techniques of Gene Editing in Pigs for Xenotransplantation
The most advanced pigs carry ten genetic modifications: four pig genes inactivated and six human genes added. Hearts and kidneys from these animals have been tested in preclinical models with brain-dead recipients, and the first two clinical pig-to-human heart transplants were performed at the University of Maryland.8Physiological Reviews. Physiological basis for xenotransplantation from genetically modified pigs to humans Neither patient survived long-term, but the surgeries proved that a gene-edited pig heart can function in a human chest. The field is still working through immunological and physiological barriers, but genetically engineered pigs are widely regarded as the most promising source of transplantable organs outside of human donors.9PubMed Central. Genetically engineered pigs for xenotransplantation: Hopes and challenges
Cellular Rejuvenation
A cluster of genes called the Yamanaka factors can reprogram adult cells back into a stem-cell-like state. Full reprogramming turns a skin cell into a blank slate, but partial reprogramming, where the factors are active for a limited time, appears to reverse some markers of aging without erasing the cell’s identity. In one study, old mice that received a gene therapy delivering three of the four Yamanaka factors saw their median remaining lifespan more than double compared to untreated controls, along with improvements in several health measures.10PubMed Central. Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice
The approach has also been tested in the brain. Researchers selectively activated Yamanaka factors in neurons of aged mice and found that the treatment reversed age-related changes and improved memory performance without causing the neurons to lose their specialized identity.11Communications Biology. In vivo cyclic overexpression of Yamanaka factors restricted to neurons reverses age-associated phenotypes and enhances memory performance The risk of uncontrolled reprogramming, which could lead to tumor formation, is the central safety concern. These are mouse studies, and the gap between rejuvenating a mouse and safely rejuvenating a human organ is enormous. Still, several biotech companies are pouring serious money into developing partial reprogramming therapies for age-related diseases.
Expanding the Genetic Alphabet
All life on Earth runs on a four-letter genetic alphabet: A, T, G, and C. Synthetic biologists have created artificial base pairs that function as a third pair alongside the natural two, effectively expanding the alphabet to six or more letters. These unnatural base pairs can be copied by standard lab enzymes, transcribed into RNA, and in some cases translated into proteins containing amino acids that do not exist in nature.12PubMed Central. Unnatural base pair systems toward the expansion of the genetic alphabet in the central dogma
Why bother? Because a larger alphabet creates new codons, the three-letter words that specify which amino acid goes where in a protein. More codons mean you can direct cells to incorporate non-natural amino acids at specific sites, producing proteins with chemical properties that evolution never explored.13PubMed Central. Expansion of the genetic code via expansion of the genetic alphabet Applications range from new classes of drugs to materials with novel functions. The technology also introduces new physicochemical properties into nucleic acids and proteins, expanding the toolkit for diagnostics and therapeutics.14PubMed. Genetic alphabet expansion biotechnology by creating unnatural base pairs It is still largely a research-stage technology, but the implications for drug design and industrial biotechnology are significant.
Organs on Chips
Animal models are poor predictors of how drugs will behave in humans. Organ-on-a-chip devices aim to close that gap. These are microfluidic platforms, roughly the size of a USB drive, lined with living human cells cultured under fluid flow to mimic the mechanical and biochemical environment of a real organ. They can recreate lung tissue that breathes, gut tissue that contracts, and liver tissue that metabolizes drugs.15Nature Reviews Genetics. Human organs-on-chips for disease modelling, drug development and personalized medicine
A key advantage for drug development is the ability to integrate drug metabolism and toxicity testing in a single device. Researchers have built organ chips that process a drug the way the liver would and then expose a second tissue to the metabolites, capturing toxic effects that a standard cell culture would miss entirely.16PubMed Central. Drug Toxicity Evaluation Based on Organ-on-a-chip Technology: A Review Multi-organ chips linking several tissue types are now being used to model whole-body responses, rare genetic disorders, and even host-microbiome interactions. The FDA has signaled interest in accepting organ-chip data as part of drug safety submissions, which could eventually reduce the number of animals used in preclinical testing.17Journal of Cellular Physiology. Organ‐on‐chip models: Implications in drug discovery and clinical applications
Food Without the Farm
Precision fermentation uses microorganisms, most commonly yeast, as factories for producing specific food proteins. Rather than milking a cow, you can program yeast to express the same casein or whey proteins found in dairy, harvest the protein, and use it in food products. The same approach works for egg proteins, muscle proteins, plant hemoglobin (the molecule that makes plant-based burgers taste meaty), and even sweet-tasting proteins and ice-binding proteins used in frozen desserts.18Comprehensive Reviews in Food Science and Food Safety. Precision cellular agriculture: The future role of recombinantly expressed protein as food
The bottleneck is economics. Production costs remain high, scalability is limited, and the functional performance of fermentation-derived proteins does not always match the conventional version. Hybrid approaches that combine precision-fermented proteins with plant-based ingredients or cultivated animal cells are being explored to bring costs down and improve texture and taste.19PubMed. Precision fermentation and recombinant proteins as enabling technologies for scalable cellular agriculture Several products, including animal-free whey and egg white, are already on the market in some countries. Whether precision fermentation can scale to meaningfully displace conventional agriculture depends on breakthroughs in bioreactor engineering and fermentation optimization that have not happened yet.
Engineering Ecosystems
Some of the boldest applications of emerging biotechnology aim to reshape entire ecosystems. Gene drives are engineered genetic elements that spread through a wild population far faster than normal inheritance would allow. In one proof-of-concept system targeting the malaria mosquito, a CRISPR-based gene drive copied antimalarial genes from one chromosome to its partner with greater than 98% efficiency in the germline.20Proceedings of the National Academy of Sciences. Highly efficient Cas9-mediated gene drive for population modification of the malaria vector mosquito Anopheles stephensi Modeling studies suggest that a gene drive targeting female fertility in malaria-carrying mosquitoes could reduce regional vector populations by roughly 95% within four years of release, assuming no resistance emerges.21BMC Biology. Modelling the suppression of a malaria vector using a CRISPR-Cas9 gene drive to reduce female fertility
The technology is genuinely transformative and genuinely alarming. Releasing a self-spreading genetic modification into a wild population is irreversible in any practical sense. Ecological side effects are difficult to predict, and the governance frameworks for approving such a release barely exist. Meanwhile, in agriculture, CRISPR is being used for less dramatic but still important work: editing crop genomes to improve drought and heat tolerance. Biotechnological tools combined with beneficial soil microbes, such as nitrogen-fixing bacteria and mycorrhizal fungi, are being developed to help staple crops like sorghum withstand climate stress.22PubMed Central. Advancing Climate-Resilient Sorghum: the Synergistic Role of Plant Biotechnology and Microbial Interactions
Engineered Microbes as Medicine
Your gut contains trillions of bacteria, and their composition affects everything from digestion to immune function to mental health. Engineered live biotherapeutic products are genetically modified microbes designed to perform a therapeutic function inside the body: secreting a missing enzyme, sensing inflammatory markers and responding with anti-inflammatory molecules, or targeting specific sites in the gut to deliver a drug locally.23PubMed Central. Discovery and delivery strategies for engineered live biotherapeutic products Several candidates are in clinical trials for conditions including inflammatory bowel disease and metabolic disorders.24PubMed Central. Microbiome engineering: engineered live biotherapeutic products for treating human disease
The appeal is that a living therapeutic can, in theory, be self-sustaining: you take one dose, the engineered microbe colonizes your gut, and it keeps producing its therapeutic payload. In practice, colonization is unreliable, engineered organisms can evolve away from their designed function, and regulatory agencies are still figuring out how to evaluate a drug that is alive and capable of reproducing.
Living Materials and Cell-Free Manufacturing
Engineered living materials are a new category of material that is synthesized or populated by living organisms. A concrete seeded with bacteria that produce calcium carbonate, for example, could heal its own cracks. These materials can sense their environment, self-repair, and in some cases self-replicate.25Matter. Make engineered living materials carry their weight Potential applications span medicine, environmental cleanup, and manufacturing, though most are still in the lab.26ACS Synthetic Biology. Toward Practical Applications of Engineered Living Materials with Advanced Fabrication Techniques
On the manufacturing side, cell-free synthesis strips out the cellular machinery, ribosomes, enzymes, energy molecules, and runs it in a test tube without any living cell. This lets researchers rapidly test biosynthetic pathways and produce specialized proteins, including ones that are difficult to make inside living cells.27PubMed Central. Cell-Free Synthesis: Expediting Biomanufacturing of Chemical and Biological Molecules Cell-free systems can overcome bottlenecks that plague traditional cell-based production, such as toxicity to the host cell or misfolding of complex proteins.28PubMed. Cell-free protein synthesis: advances on production process for biopharmaceuticals and immunobiological products The vision is on-demand, decentralized manufacturing: a portable system that produces a needed drug or diagnostic reagent wherever it is required, without cold chains or factory infrastructure.
Biosecurity and the Governance Gap
The same tools that enable researchers to design vaccines and edit disease genes also make it easier to synthesize dangerous pathogens. DNA synthesis technology, a foundational capability for synthetic biology, has already been used to reconstruct viruses in the lab. International bodies have recommended common screening standards for DNA synthesis orders to flag potentially dangerous sequences, and guidelines like those from the U.S. Department of Health and Human Services have been updated to address the evolving synthesis industry.29Journal of Biosafety and Biosecurity. Challenges and recent progress in the governance of biosecurity risks in the era of synthetic biology But compliance with screening guidelines remains voluntary for many companies, and international regulatory coordination is patchy at best.
The regulatory challenge extends to less dramatic products. Cell and gene therapies, for instance, have received strong support from expedited development pathways and orphan drug designations, but that regulatory enthusiasm has not always translated into high-quality submissions. Reviews of approved cell and gene therapies have found that the most frequent quality objections concern manufacturing consistency, assay validation, and stability data, meaning that companies sometimes rush through the science to capitalize on fast-track approvals.30PubMed Central. Research Outlook of Cell Gene Therapies Development and Approval from Quality and Regulatory Perspective The intellectual property landscape adds another layer of complexity: CRISPR patent disputes have been contentious, though broad licensing has so far kept the technology accessible to both academic and commercial users.31PubMed. The CRISPR Patent Landscape: Past, Present, and Future
Biological Data Storage and Diagnostics
DNA is an astonishingly dense storage medium. In principle, a single gram of DNA can hold an exabyte of data, orders of magnitude beyond any conventional hard drive, and it remains stable for centuries under the right conditions.32PubMed Central. DNA storage—from natural biology to synthetic biology Several groups have successfully encoded and retrieved text, images, and video from synthetic DNA strands. The barriers to practical use are cost and speed: writing data into DNA and reading it back out are both slow and expensive compared to electronic storage. For archival purposes, though, where data needs to last decades and access speed is less important, DNA storage may eventually find a niche.
On the diagnostic side, CRISPR is being repurposed from a gene-editing tool into a detection platform. CRISPR-Cas12a, a variant of the system, can be paired with biosensors to create portable, point-of-care diagnostic devices. One such system detects human papillomavirus DNA using a photoelectrochemical readout on a disposable electrode, combining CRISPR’s target specificity with a simple electronic output that could work outside a traditional lab.33PubMed. CRISPR-Cas12a-Derived Photoelectrochemical Biosensor for Point-Of-Care Diagnosis of Nucleic Acid Similar CRISPR-based diagnostics are being developed for infectious diseases, genetic conditions, and cancer biomarkers, with the aim of bringing lab-grade sensitivity to a handheld device.
Brain-Computer Interfaces
Neurotechnology sits at the intersection of biotechnology and electronics. Flexible high-density microelectrode arrays represent a significant advance over the rigid electrode arrays that have been used in brain-computer interfaces for years. These newer arrays conform to the brain’s curved surface, record from more neurons simultaneously, and cause less tissue damage over time, which improves long-term signal stability.34PubMed. Advances in flexible high-density microelectrode arrays for brain-computer interfaces The clinical applications being pursued most urgently are restoring communication and movement for people with paralysis, but the same technology platform could eventually be used for treating neurological and psychiatric conditions through precisely targeted stimulation. The field sits earlier on the translational timeline than gene editing or mRNA therapeutics, with most devices still in small clinical trials or preclinical testing, and the ethical questions around elective neural enhancement are only beginning to be addressed.
Plastic-Eating Enzymes
Petroleum-based plastics accumulate in the environment because almost nothing in nature can break them down efficiently. Researchers have identified and are engineering enzymes capable of degrading polyethylene terephthalate, one of the most widely used plastics, into its chemical building blocks.35PubMed Central. Engineering Plastic Eating Enzymes Using Structural Biology The original discovery came from bacteria found in a Japanese recycling facility, and protein engineering has since improved the enzymes’ speed and thermal stability. The long-term vision is a biological recycling system that breaks plastic waste down into monomers that can be repolymerized into new plastic, creating a true circular economy for materials that currently end up in landfills and oceans. Scaling the technology to handle industrial volumes of waste remains an open engineering challenge, but pilot plants are already operating.